Cannabis Cultivar Collection Across Canada and the International Markets

Segra Enters Agreement to Offer Allele’s Proven Cannabis Cultivar Collection Across Canada and the International Markets

By /

VANCOUVER, (March 10, 2021) Segra International Corp. and Allele Genetics, a subsidiary of Catalyst BC, are pleased to announce they have entered into an exclusive agreement to distribute Allele’s collection of data-backed “Proven Cultivar” cannabis cultivars within the Canadian market and other legal international markets. Allele’s Proven Cultivars have been grown at both a commercial scale and for breeding and agronomic dataset development for over a decade by one of the most experienced operational teams in the industry, Catalyst BC, and its affiliates. Harnessing the strength of its proven Plant Tissue Culture technology, Segra will be releasing Allele cultivars on an ongoing basis as part of its Verified Clean Stock program.

Allele’s Proven Culticars have been carefully selected based on cannabinoid profile and yield, terpene profiles, and key characteristics such as maturation cycle time, high-density trichome area index (“TAI”), mold/mildew resistance and high bract-to-leaf ratios. The ongoing cultivar releases will represent abroad palate of terpene profiles yielding flavors and aromas ranging from citrus to berry and cake to gas–flavors the modern cannabis consumer desires. Amplifying Allele’s Proven Winners with the power of Segra’s tissue culture technologies will ensure consistently high-performing plants that are, as with all Segra tissue culture plants, Verified Clean Stock. Segra and Allele are confident that this offering will help producers turn better plants into better profits.

“Segra is thrilled to be partnering more closely with Allele and able to offer a portion of their data-backed collection, through tissue culture, to operators,” said Segra CEO Jamie Blundell. “Allele has developed an incredible portfolio of diverse, premium cannabis cultivars through tremendous industry expertise and experience. Partnering with top genetics consultants, like Allele Genetics, is central to Segra’s ability to continuously provide our clients with the cultivars of the future, and we are keen to showcase how top genetics, paired with the performance of tissue culture, will lead to operational optimization for Canadian LPs.”

“Today’s cannabis consumer desires potency, flavor, and aroma. Allele’s Proven Cultivars is a collective team effort to enhance and elevate the evolving consumer experience. We have spent the better part of a decade collecting critical agronomic data and consumer feedback necessary to drive cannabis cultivar identification, selection, collection, trialing, and optimization.” Said Eric Forington, Director of Plant Breeding and Genetics at Allele Genetics. Our primary goal is an emphasis on both consumer experience, through consistently high-quality, high-potency, flavor and aroma-forward flower, and LP success by allowing superior genetics to do the heavy agronomic lifting. We are incredibly excited to support the distribution of our Proven Cultivars in the Canadian and legal global import/export markets through Segra’s proprietary micropropagation process and look forward to partnering with Segra to provide true-to-type, commercially viable plantlets at scale.”

To learn more about this partnership and how Segra and Allele’s Tissue Culture plantlets can improve your output and reduce risk, please contact Segra at info@segra-intl.com.
 
About Allele:
 
Allele Genetics has been redefining the boundaries of high THC, high terpene cannabis breeding for over two decades and has consistently raised the bar for Top-Shelf cannabis genetics. Our breeding programs are focused on ultra-high cannabinoid content and selections from our award-winning genetics catalog consistently test over 30% THC. Allele Genetics combines over 20 years of traditional commercial cannabis breeding experience with the latest science and technology, including micro-propagation and molecular breeding tools, to enhance trait stability and provide genetic identification for our unique cannabis cultivars. Learn more about our team here.
 
About Segra:
 
Segra is an agriculture technology company offering plant tissue culture and DNA fingerprinting services to accelerate the advancement of the cannabis industry. The company’s proprietary technologies empower its clients to drive financial performance and mitigate risk while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce disease-free, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally. To support this vision, Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, plant tissue culture, and regulatory compliance. Learn more about Segra here.
 
For Further Information:
 
Carson Otto
 
Forward-Looking Information:
 
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, uncertainties, and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by applicable law.
 

Additional Resources

Consulting Services For Cannabis, Hemp, Psilocybin, and Natural Medicine

Testimonials and Public Relations

Latest Articles

  • Healthy indoor cannabis cultivation facility operating under a Virginia cannabis cultivation license.
    Virginia Cannabis Cultivation License (2027): The Tiered System Explained
    For operators whose strength is growing cannabis, Virginia’s emerging adult-use market presents a significant opportunity – and a cultivation license is the gateway to it. The June 2026 framework authorizes the Virginia Cannabis Control Authority (CCA) to begin accepting license applications on or after February 1, 2027 and issuing licenses on or after May 1, 2027. It also establishes five cultivation tiers with maximum canopies ranging from 5,000 to 35,000 square feet.
  • Close-up of a cannabis cultivation professional tending to a young flowering plant in a commercial Virginia facility.
    Virginia Impact Cannabis License (2027): Social Equity & the Equity Business Loan Fund
    Virginia’s adult-use cannabis framework creates a meaningful pathway for applicants from communities and backgrounds affected by cannabis prohibition and enforcement. The law does not create a separate, stand-alone impact license. Instead, it creates an impact-licensee designation that qualifying applicants may pursue alongside an underlying marijuana establishment license, such as retail, cultivation, processing, microbusiness, transportation, delivery, or testing.
  • Two cultivation employees harvesting fully flowered cannabis at a licensed Virginia microbusiness facility.
    Virginia Cannabis Microbusiness License (2027): Eligibility & the Two-Location Model
    This guide explains the initial eligibility pathways for the licenses the CCA may issue by May 1, 2027, the difference between a microbusiness license and an impact designation, the indoor and outdoor cultivation limits, the precise rules governing two locations, and the financial, security, and operational readiness standards applicants should prepare to demonstrate. Several implementation details – including fees and the specific combination of privileges the CCA will authorize – still depend on forthcoming regulations.
  • Virginia Dual-Use Cannabis Conversion (2027): The $10M Medical-to-Adult-Use Pathway
    For Virginia’s existing medical cannabis operators, the 2026 retail framework created a distinct and high-stakes transition: pharmaceutical processors may apply for verification to exercise dual-use privileges and serve both registered medical patients and adult-use customers. The pathway covers the processor and its permitted cannabis dispensing facilities, and it carries a one-time $10 million fee, a required medical cannabis program preservation plan, an impact-licensee business accelerator commitment, and a firm May 1, 2027 payment or installment-plan deadline.
  • Michael Williamson of Catalyst BC in the aisle of a Virginia cannabis cultivation facility under construction.
    Virginia Cannabis Facility Design & Build-Out for the 2027 Market
    This guide covers the major considerations involved in planning and building a Virginia cannabis facility, with a focus on retail and cultivation operations and additional considerations relevant to processors and microbusinesses. It is written from the build side of the business, because that is where many otherwise-strong applicants stumble: they underestimate utility needs, local approvals, security infrastructure, commissioning, and the time required to convert a site into an inspection-ready operation.
  • Customers viewing cannabis products through a display case at a Virginia dispensary.
    How to Open a Dispensary in Virginia: The 2027 Retail Store License Guide
    If you’ve been waiting for the chance to open a cannabis dispensary in Virginia, that chance is now real. With the General Assembly’s June 2026 approval of a regulated retail framework, Virginia is on track to begin adult-use sales on July 1, 2027, and the Cannabis Control Authority (CCA) is expected to open license applications on February 1, 2027.

Explore Our Articles

cannabis applications Cannabis Bar Cannabis Business Optmization cannabis careers Cannabis Compliance Cannabis Consumption Cannabis Consumption Bar Cannabis Inventory Management Systems Cannabis Investors cannabis jobs Cannabis Legalization cannabis licensing Cannabis Lounge cannabis marketing Cannabis Operational Procedures cannabis outreach Cannabis Regulations Cannabis Security Cannabis Software Cannabis Startup Cannabis Supply Chain Cannabis Technology Colorado controlled environment agriculture Cultivation cultivation facility Dispensary Design facility design Financial Planning HVAC HVACD Iowa Kansas Legal Update Legislation Medical Cannabis Minnesota Natural Medicine Nebraska New York Odor Control Oregon Psilocybin Psychedelics Recreational Cannabis

Scroll to Top